Evaluation of the dermal irritation and skin sensitization due to thiocolchicoside transdermal drug delivery system

Nishant Thakur; Bhupinder Kaur; Chandan Sharma; Manish Goswami

doi:10.53730/ijhs.v6nS3.6274

Authors

Nishant Thakur University Institute of Pharma Sciences, Chandigarh University
Bhupinder Kaur
bhupinder21990@cumail.in
University Institute of Pharma Sciences, Chandigarh University
Chandan Sharma University Institute of Pharma Sciences, Chandigarh University
Manish Goswami Saraswati Pharmacy college, Gharuan, Mohali, Punjab

Keywords:

thiocolchicoside, skin irritation, sensitization, dermal

Abstract

The skin irritation and sensitization potential of the new transdermal patch of the Thiocolchicoside formulated with Dura 87-6908 was evaluated on the rabbits and guinea pig as per the standard guidelines of OECD. Skin irritation test was performed on the rabbits by applying the placebo patch for 72 hours and dermal reactions like edema, erythema were noted. No clinical signs or dermal reactions were observed in the rabbits. Sensitization potential was measure on the guinea pig and animal was challenged to transdermal therapeutic system of the Thiocolchicoside, negative control group while group exposed to CDNB produced the sensitization reactions. These findings proved that Thiocolchicoside does not produce any dermal toxicity, irritation and sensitization and hence it is safe for dermal use.

Downloads

Download data is not yet available.

References

M. Carta et al., “The muscle relaxant thiocolchicoside is an antagonist of GABAA receptor function in the central nervous system,” Neuropharmacology, 2006, doi: 10.1016/j.neuropharm.2006.05.023. DOI: https://doi.org/10.1016/j.neuropharm.2006.05.023

J. R. T. Patil P.H., Patil P.R., “Formulation and Evaluation of Semisolid preparation (Ointment, Gel & Cream) of Thiocolchicoside,” J. Pharm. Biomed. Sci., 2011.

R. K. Nanda, S. S. Patil, and D. A. Navathar, “Chiotsan nanoparticles loaded with thiocolchicoside,” Der Pharma Chem., 2012.

G. C. Ceschel et al., “In vitro permeation screening of a new formulation of thiocolchicoside containing various enhancers,” Drug Deliv. J. Deliv. Target. Ther. Agents, vol. 9, no. 4, pp. 259–263, 2002, doi: 10.1080/10717540260397882. DOI: https://doi.org/10.1080/10717540260397882

Z. Abbas and S. SACHIN, “Indian Journal of Novel Drug Delivery,” Indian J. Nov. Drug Deliv., vol. 4, no. 1, pp. 2–16, 2012.

C. Greve and L. Jorgensen, “Therapeutic Delivery,” Ther. Deliv, vol. 7, no. 2, pp. 117–138, 2016, doi: 10.4155/tde.15.92. DOI: https://doi.org/10.4155/tde.15.92

D. Psimadas, P. Georgoulias, V. Valotassiou, and G. Loudos, “Molecular Nanomedicine Towards Cancer :,” J. Pharm. Sci., vol. 101, no. 7, pp. 2271–2280, 2012, doi: 10.1002/jps. DOI: https://doi.org/10.1002/jps.23146

H. O. Ammar, M. Ghorab, S. A. El-Nahhas, and R. Kamel, “Polymeric matrix system for prolonged delivery of tramadol hydrochloride, part II: Biological evaluation,” AAPS PharmSciTech, 2009, doi: 10.1208/s12249-009-9294-2. DOI: https://doi.org/10.1208/s12249-009-9294-2

E. Sánchez-López et al., “Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma,” Small, vol. 14, no. 2, p. 1701808, Jan. 2018, doi: 10.1002/smll.201701808. DOI: https://doi.org/10.1002/smll.201701808

E. Sánchez-López et al., “PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization,” Colloids Surfaces B Biointerfaces, vol. 145, pp. 241–250, Sep. 2016, doi: 10.1016/j.colsurfb.2016.04.054. DOI: https://doi.org/10.1016/j.colsurfb.2016.04.054

S. S. Bhattacharya and S. Banerjee, “Skin permeation of buflomedil form adhesive matrix patches,” J. Adhes. Sci. Technol., vol. 29, no. 10, pp. 925–942, May 2015, doi: 10.1080/01694243.2015.1009722. DOI: https://doi.org/10.1080/01694243.2015.1009722

A. K. Banga et al., “Development of a transdermal delivery system for tenofovir alafenamide, a prodrug of tenofovir with potent antiviral activity against hiv and hbv,” Pharmaceutics, vol. 11, no. 4, 2019, doi: 10.3390/pharmaceutics11040173. DOI: https://doi.org/10.3390/pharmaceutics11040173

J. Wang et al., “Evaluation of dermal irritation and skin sensitization due to vitacoxib,” Toxicol. Reports, vol. 4, no. June, pp. 287–290, 2017, doi: 10.1016/j.toxrep.2017.06.003. DOI: https://doi.org/10.1016/j.toxrep.2017.06.003

B. Sadarani et al., “Enhanced skin permeation of Methotrexate from penetration enhancer containing vesicles: In vitro optimization and in vivo evaluation,” Biomed. Pharmacother., vol. 114, no. July 2018, p. 108770, 2019, doi: 10.1016/j.biopha.2019.108770. DOI: https://doi.org/10.1016/j.biopha.2019.108770

V. V. Yamsani, M. K. Mudulaghar, S. Afreen, S. Wajid, S. K. Ravula, and S. D. Babelghaith, “Formulation design and in vitro ex vivo evaluation of transdermal patches of Cinnarizine,” Pak. J. Pharm. Sci., vol. 30, no. 6, pp. 2075–2083, Nov. 2017.

European Medicines Agency, “Guideline on quality of transdermal patches,” Comm. Hum. Med. Prod., vol. 44, no. October 2014, pp. 1–27, 2014, [Online]. Available: www.ema.europa.eu/contact.

S. Gholve, “A Systematic Review on Transdermal Patches,” no. September, 2017.

N. Akhtar, V. Singh, M. Yusuf, and R. A. Khan, “Non-invasive drug delivery technology : development and current status of transdermal drug delivery devices , techniques and biomedical applications Developmental perspective : an introduction to TDDS,” pp. 1–30, 2020. DOI: https://doi.org/10.1515/bmt-2019-0019

Y. Mamta, N. Satish, and B. Jitendra, “A review on : Transdermal patches for pain management,” no. January 2010, pp. 55–68, 2014.